New target for cancer therapy
November 3 , 2024
19 days
93
- Researchers have found a promising new target for cancer therapy, for patients who develop resistance to existing treatments.
- The scientists focused on a DNA repair enzyme, TDP1, which may be key to a new combination therapy.
- Current cancer drugs like Camptothecin, Topotecan, and Irinotecan target the enzyme Topoisomerase 1 (Top1) crucial for DNA replication.
- However, cancer cells often become resistant to these drugs.
- But these two proteins, Cyclin-dependent kinase 1 (CDK1) and Tyrosyl-DNA phosphodiesterase 1 (TDP1), play critical roles in this repair process.
Post Views:
93